Introduction
The study of stem cell biology as a scientific discipline distinct from its roots in hematology, cancer biology, immunology, developmental biology, and neuroscience traces back to landmark findings in the late 1990s. Such findings include the cloning of Dolly the sheep (Campbell et al., 1996) and the first successful derivation of human embryonic stem (ES) cells (Thomson et al., 1998) . In a remarkably short time-span, the field has attracted an extraordinary level of public expectation and government support for its potential applications in regenerative medicine, but it has also attracted significant political and ethical controversy over the use and manipulation of human biologic materials in some studies. Research and policy approaches to stem cell biology have coevolved, and the field has become a truly global enterprise.
One striking aspect of the international stem cell research community is the diversity and depth it has achieved in a short span. A number of smaller nations, such as Israel, Sweden, and Singapore, have punched well above their weight by identifying and concentrating their efforts in specific niches within the field, whereas many other countries with comparatively scant prior experience in advanced biomedical research and development, notably China and Korea, have built competitive research facilities and programs from the ground up. Meanwhile, religious and political debates over issues such as the use of human embryos for research, somatic cell nuclear transfer (''therapeutic cloning''), and the generation of humananimal hybrids have created problems for, and in some cases prevented, work in this field in major research nations, including the United States, Germany, and Australia. Indeed, the funding restrictions on human ES cell research in the USA might have inspired countries, many of them in Asia, that had not historically conducted leading biomedical research to promote such research through specific regulatory and funding initiatives.
Despite the limitations imposed on federal funding, however, the United States has showed great robustness and ingenuity in developing alternative funding sources for stem cell research, for example through industry and philanthropic investment, patient activism, and funding initiatives by individual states. This defederalization of stem cell research funding is exemplified by the California Institute of Regenerative Medicine, which has led a $3 billion commitment over 10 years (CIRM, 2011) . Other factors, including the country's powerful research universities, a tradition of scientific entrepreneurialism, regulatory clarity, and the sheer size of its life sciences and biotechnology communities have ensured that even in the face of numerous nonscientific hurdles and intense international competition, the United States remains the leader in most important metrics of productivity, including publications, patents, and funding. Intraregional cooperation and outreach has also been a successful feature of stem cell science within the EU. In one famous example, a collaboration between scientists and clinicians in Spain, Italy, and the UK achieved a breakthrough proof-ofconcept demonstration of the decellularization-recellularization approach to tissue replacement in 2009 when they used a patient's own stem cells to repopulate a transplantable allogeneic tracheal segment that had been denuded of the donor's cells (Macchiarini et al., 2008) The unifying structure of the EU has not, however, entirely eliminated policy differences between countries, and it has failed to bridge the considerable gap between member states in areas such as human ES cell research regulations. Recently, EU stem cell scientists have expressed growing concern over the possibility that patents based on human ES cell technologies will be disallowed on the grounds that they would offend public morality. A coalition of prominent scientists have argued that such a decision would do irreparable harm to the ability of EU scientists and companies to compete in this area.
European Unity

Asia Comes of Age
The governments of many nations in Asia and Oceania have shown extraordinary support for the development of stem cell research and application within their borders. China, Korea, Singapore, India, and Taiwan have all invested unprecedented amounts in stem cell research since 2001, and Japan and Australia have built on their historical strengths in basic biology and clinical development to create leading stem cell institutes in Kyoto, Kobe, and Melbourne (Sipp, 2009 ). Progress has not always been smooth-the scandal surrounding WooSuk Hwang's fraudulent claims of somatic cell nuclear transfer highlighted weaknesses in the funding and oversight systems that Korea, to its credit, was quick to rectify-and, with the exception of Japan and more recently China, productivity has been incommensurate with funding levels.
The Asia-Pacific region lacks a governing organization equivalent to that of the EU, and this defecit continues to make the establishment of region-wide stem cell research programs and collaborations difficult. In 2007, Stem Cell Network: Asia-Pacific (SNAP) was launched by scientists from eight countries in the region, but the organization has failed to attract sustained funding or activity levels in recent years. At the national level, many Asian countries have organized strong national stem cell societies; some, such as those in Singapore, Taiwan, and Korea, have hundreds of members representing dozens of labs. Japan lacks a stem cell society per se, but the Japanese Society for Regenerative Medicine has well over 2,000 members. Unfortunately, the lack of a regional entity to coordinate stem cell research and development has led in some cases to redundancy and needless competition in the building of stem cell banks and the scheduling of international symposia.
Although regulations of the use of human embryos for research have tended to be quite favorable in much of the region, several countries have been caught off guard by a lack of preparedness for the clinical translation of stem cell research, and numerous clinics advertising spurious stem cell injections for the treatment of a wide range of medical conditions have put patients in harm's way and damaged the reputations of legitimate scientists working in the same country. Efforts have been made to address such unregulated uses of stem cells and have resulted in new regulations in Thailand and China, and the national prosecutor's office in Korea investigated one company that had been recruiting patients to receive stem cell injections overseas.
Stem Cells on the Global Stage
A number of organizations bring together scientists and stakeholders from around the world to promote the field. Preeminent among these is the International Society for Stem Cell Research (ISSCR), with more than 3600 members from more than 40 countries representing academia, industry, government, and philanthropic organizations (ISSCR, 2011) . The ISSCR works to promote global discussion on the latest advances in stem cell research in its annual meetings, which are held on a rotating basis in North America, Europe, and the Asia-Oceania region, as well as to conduct educational and public-engagement activities around the world. It has produced consensus guidelines on human ES cell research and the clinical translation of stem cell technologies, as well as information for patients considering stem cell treatments.
Other, more clinically oriented international groups focusing on stem cells and regenerative medicine include the International Society of Cellular Therapy (ISCT) and TERMIS, both of which gather researchers and clinicians from academia and industry to discuss the development of human cell-and tissue-based medical products and procedures. Support for international research efforts, with a particular focus on human ES cell characterization, banking, and cultural standards, has been provided for nearly ten years by the International Stem Cell Forum, which comprises nearly 20 national and other funding agencies. The International Consortium of Stem Cell Networks brings together support and promotion organizations from many countries, most notably Canada, Australia, and Germany. Industry meetings, research institutes, and national societies all also regularly hold international conferences and workshops on the full spectrum of stem cell research, ensuring that scientists in the field are confronted by an embarrassment of choices when making their conference schedules.
New Discoveries, New Directions
Much of the first half of the first decade of the 21 st century saw the field dominated by controversy and uncertainty over questions such as the moral status of human blastocysts, the comparative advantages of ES and somatic stem cells, and the rush to develop stem cell-based transplantation procedures for use in regenerative medicine. The first report of induced pluripotent stem (iPS) cells in 2006 (Takahashi and Yamanaka, 2006 ) had a transformative effect on the field because it paved the way to an alternative source for human pluripotent stem cells; this new source was much less encumbered than human ES cell research by ethical concerns. Although the initial discovery was made by a Japanese laboratory, it paradoxically strengthened the hand of US-based researchers who were freed from the funding restrictions and legal and political disputes that had dogged human ES cell research, and at present it is the US rather than Japan that dominate iPS cell research. The Japanese government has, however, invested heavily in the field and has created a Center for iPS Cell Research and Application led by Shinya Yamanaka at Kyoto University; China has also ramped up its stem cell investment, including its investment in many iPS cell labs, in its most recent national 5 yr spending plan. Technological developments have also led to a number of industry-funded clinical trials of stem cell-based treatments for conditions such as heart failure, spinal cord injury, cerebrovascular accident, and amyotrophic lateral sclerosis. In all cases, however, these studies are at the earliest stages of safety testing, and the road to regulatory approval will doubtless be long and fraught with challenges. After the excitement of the first days of intensive stem cell research, the reality of the unique challenges of cell-based products has set in. Scientists, physicians, and regulators alike have recognized the risks and limitations imposed by the ability of stem cells of various types to proliferate, differentiate, home to wound and tumor sites, and secrete multiple molecular factors; indeed, nearly every property of potential clinical benefit also represents a potential risk. Whether stem cells or their derivatives will be able to integrate into target tissues, particularly dynamic or complex environments such as cardiac muscle or the nervous system, and lead to the restoration of physiological function remains very much an open question, and concerns have also been raised that some degenerative diseases might be associated with pathogenic tissue environments capable of damaging or transforming stem cells, which might further complicate their use in the treatment of such conditions. Furthermore, the longterm genetic and karyotypic stability of stem cells in vivo outside the hematopoietic system is largely unknown, and any treatment protocol that calls for cells to functionally integrate and survive for the life of the patient will need to include provisions for follow-up and surveillance over the long term. It will be important for scientists, policymakers, and funding bodies to remain focused and alert for opportunities in the development of true stem cell-based treatments while maintaining realistic and responsible oversight to ensure patient safety and public trust.
At the same time, a number of potential stem cell applications that do not follow the ''cell therapy'' paradigm have gained prominence in recent years. The advent of human iPS cells has opened up possibilities for the generation of large, pure populations of differentiated cells, such as cardiomyocytes, hepatocytes, and neurons of various types, which could prove invaluable as test beds for use in drug discovery, toxicology testing, and disease modeling. These have the added advantage of serving as a potential replacement for some types of animal studies, provided that human cells in vitro can be shown to differentiate into physiological tissue and mimic disease states with sufficient accuracy. Stem Cells for Safer Medicine (SC4SM, 2010), a coalition that includes three major drug companies, has already been formed with the aim of exploring the possibilities of stem cells in pharmaceutical development.
Results from some clinical studies using mesenchymal stem cells (MSCs) have shown transient benefits but poor cell survival, leading to speculation that the effects might be due to paracrine secretion of cytokines and other factors, which might trigger wound healing or angiogenesis or modulate the immune response. Bio-prospecting research into such stem cells might reveal the specific cocktails of factors able to elicit such healing responses, and if isolated and tested, such factors might one day lead to the development of ''cell therapy without cells.'' Similarly, there have been proposals to use MSCs, which have been shown to home to sites of tissue damage and tumorigenesis, as vehicles for the delivery of bioactive molecules or nanomaterials. Finally, the discovery that cell fates can be reprogrammed, as evidenced by the transformation of fibroblasts into pluripotent stem cells in the iPS cell process, might lead to new advances in direct reprogramming between differentiated cells types; such reprogramming has already been demonstrated in the conversion of exocrine into endocrine cells in the pancreas (Zhou et al., 2008) and in the conversion of B cells into macrophages in the blood system (Bussmann et al., 2009) . Although these alternative uses of stem cells might have less charismatic appeal than the classic concept of cell transplantation, they could allow important successes in the near term while studies on more challenging clinical applications move forward.
The unregulated use of stem cells in medicine, often referred to as ''stem cell tourism,'' remains one of the greatest threats to patients and to the field itself (Taylor et al., 2010) . Hundreds of companies market untested stem cell products and injections for an extremely broad range of diseases, many of which, such as spinal cord injury, ALS, autism, Parkinson disease, and multiple sclerosis, affect the nervous system. Strides have been made in reining in such unscrupulous behavior after multiple incidents of tumorigenesis and death as the result of complications following injections of cells into the brainstem or carotid artery, but companies have shown great resourcefulness in their ability to evade oversight and lure patients. The international stem cell community has been extremely active in combatting the premature commercialization of stem cell treatments and will need to continue to work with authorities, patient groups, and media organizations to inform and protect patients from such practices.
Stem cell research continues to be one of the most exciting and highly anticipated fields of biological research, and it enjoys exceptional support from funding agencies and the general public in countries around the world. The road to applications will be a long one, and numerous hurdles lie ahead. The success of the field will continue to rely heavily on fundamental research to provide a solid basis of understanding for clinical studies, and scientists in all countries will need to continue to collaborate, share, compete, and strive together if the extraordinary promise of stem cell research is to be realized.
